Jan 4, 2012 | PR-inside.com
NexImmune Appoints Kenneth Carter, PhD, as President and CEO and...
At the same time, NexImmune announced that the company has licensed the A rtificial IM mune nanotechnology for immuno-therapy, developed by Dr.
Former execs at two local biotechs create a new one
Biotech vets Alain Cappeluti, left, and Ken Carter have joined forces to launch Noble Life Sciences to provide animal studies and services.